An Immune Model to Predict Prognosis of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy Based on Support Vector Machine

• Published in: Frontiers in oncology 2021-04, Vol.11, p.651809-651809
• Main Authors: Wang, Mozhi, Pang, Zhiyuan, Wang, Yusong, Cui, Mingke, Yao, Litong, Li, Shuang, Wang, Mengshen, Zheng, Yanfu, Sun, Xiangyu, Dong, Haoran, Zhang, Qiang, Xu, Yingying
• Format: Article
• Language: English
• Subjects: breast cancer; immunity; neoadjuvant chemotherapy; Oncology; prediction; support vector machine
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2021.651809

Tumor microenvironment has been increasingly proved to be crucial during the development of breast cancer. The theory about the conversion of cold and hot tumor attracted the attention to the influences of traditional therapeutic strategies on immune system. Various genetic models have been constructed, although the relation between immune system and local microenvironment still remains unclear. In this study, we tested and collected the immune index of 262 breast cancer patients before and after neoadjuvant chemotherapy. Five indexes were selected and analyzed to form the prediction model, including the ratio values between after and before neoadjuvant chemotherapy of CD4 /CD8 T cell ratio; lymphosum of T, B, and natural killer (NK) cells; CD3 CD8 cytotoxic T cell percent; CD16 CD56 NK cell absolute value; and CD3 CD4 helper T cell percent. Interestingly, these characters are both the ratio value of immune status after neoadjuvant chemotherapy to the baseline. Then the prediction model was constructed by support vector machine (accuracy rate = 75.71%, area under curve = 0.793). Beyond the prognostic effect and prediction significance, the study instead emphasized the importance of immune status in traditional systemic therapies. The result provided new evidence that the dynamic change of immune status during neoadjuvant chemotherapy should be paid more attention.